PHGE Stock Price, BiomX Inc Quote, Chart

Market Summary

USD0.38-0.03

Delayed

-7.32%

PHGE Stock Price

View Fullscreen

PHGE RSI Chart

PHGE Valuation

Market Cap

21.0M

Price/Earnings (Trailing)

-0.8

Price/Sales (Trailing)

132.81

EV/EBITDA

-0.22

Price/Free Cashflow

-0.98

PHGE Price/Sales (Trailing)

PHGE Profitability

EBT Margin

-16548.10%

Return on Equity

-849.37%

Return on Assets

-104.55%

Free Cashflow Yield

-101.68%

PHGE Fundamentals

PHGE Revenue

Revenue (TTM)

158.0K

PHGE Earnings

Earnings (TTM)

-26.2M

Earnings Growth (Yr)

6.71%

Earnings Growth (Qtr)

30.55%

Breaking Down PHGE Revenue

Last 7 days

8.6%

Last 30 days

8.6%

Last 90 days

72.7%

Trailing 12 Months

38.6%

How does PHGE drawdown profile look like?

PHGE Financial Health

Current Ratio

1.58

Debt/Equity

1.81

Debt/Cashflow

-3.81

PHGE Investor Care

Shares Dilution (1Y)

66.45%

Diluted EPS (TTM)

0.52

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2021	158.0K	158.0K	158.0K	158.0K
2020	0	0	0	158.0K
2019	0	887.1K	522.6K	0
2018	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of BiomX Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	flynn james e	acquired	-	-	3,055,050	-
Nov 29, 2023	oron assaf	sold	-4,071	0.373057	-10,914	chief business officer
May 22, 2023	oron assaf	bought	871	0.2731	3,192	chief business officer
May 19, 2023	oron assaf	bought	1,831	0.2809	6,521	chief business officer
May 18, 2023	oron assaf	bought	327	0.2727	1,201	chief business officer
Feb 27, 2023	orbimed israel biofund gp limited partnership	bought	85,260	0.245	348,000	-
Nov 04, 2022	ugwumba chidozie	sold	-567	0.378	-1,501	-
Nov 03, 2022	ugwumba chidozie	sold	-732	0.366	-2,000	-
Nov 02, 2022	ugwumba chidozie	sold	-867	0.359	-2,416	-

Which funds bought or sold PHGE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 02, 2024	8VC GP I, LLC	unchanged	-	184,653	488,786	0.62%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	unchanged	-	-288	1,120	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	100	92.00	2,736	-%
Feb 14, 2024	Walleye Trading LLC	unchanged	-	-751	2,918	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	-	-	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-24.00	-	-%
Feb 14, 2024	JOHNSON & JOHNSON	unchanged	-	-153,605	597,353	0.01%
Feb 14, 2024	Walleye Capital LLC	unchanged	-	1,141	5,074	-%

Are Funds Buying or Selling PHGE?

Are funds buying PHGE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PHGE

No. of Funds

Unveiling BiomX Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 26, 2024	cystic fibrosis foundation	15.6%	9,330,580	SC 13G/A
Mar 25, 2024	amr action fund, l.p.	5.5%	3,054,870	SC 13G
Mar 22, 2024	flynn james e	5.53%	3,055,049	SC 13D
Mar 19, 2024	orbimed israel biofund gp limited partnership	19.9%	12,577,821	SC 13D/A
Mar 08, 2024	orbimed israel biofund gp limited partnership	9.9%	4,601,808	SC 13D/A
Feb 13, 2024	mmcap international inc. spc	3.22%	1,527,994	SC 13G/A
Feb 02, 2024	johnson & johnson	4.6%	2,113,402	SC 13G/A
Jan 30, 2024	cystic fibrosis foundation	9.90%	4,552,315	SC 13G/A
Sep 29, 2023	centaurus investments ltd	6.2%	2,839,714	SC 13G
Jun 23, 2023	burbank john howard iii	9.99%	4,598,189	SC 13G

Recent SEC filings of BiomX Inc

View All Filings

Date Filed	Form Type	Document
Apr 29, 2024	S-3	S-3
Apr 15, 2024	3	Insider Trading
Apr 15, 2024	8-K	Current Report
Apr 04, 2024	10-K	Annual Report
Apr 04, 2024	S-8	Employee Benefits Plan
Apr 03, 2024	8-K	Current Report
Apr 01, 2024	D	D
Apr 01, 2024	NT 10-K	NT 10-K
Mar 26, 2024	3	Insider Trading
Mar 26, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to BiomX Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.9B	6.8B	23.52%	-6.94%	-8.03	7	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	0.99%	-25.83%	-58.02	9.62	75.20%	68.82%
BMRN	15.7B	2.5B	-4.94%	-13.58%	76.24	6.34	13.74%	186.89%
INCY	12.1B	3.8B	-2.80%	-18.78%	16.19	3.2	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-16.72%	-43.78%	-10.82	14.42	425.83%	18.94%
BBIO	5.2B	107.9M	-4.79%	106.15%	-9.53	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	1.74%	5.10%	-14.81	13.09	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.74%	-39.00%	-10.2	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.55%	-20.97%	-45.79	3.86	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-4.91%	-11.58%	24.31	4.36	85.90%	-14.05%
NVAX	687.2M	983.7M	8.15%	-35.14%	-1.26	0.7	-50.36%	17.16%
CRBP	408.0M	881.7K	0.99%	345.87%	-9.15	466.16	-77.61%	-5.33%
INO	282.8M	4.9M	-1.94%	21.49%	-2.09	58.11	-54.97%	51.71%
IBIO	6.9M	2.1M	-32.65%	86.79%	-0.25	2.14	-13.45%	66.37%

BiomX Inc News

Latest updates

BiomX Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-	-	-	-	-	-	374,533	408,752	442,970	55,546
Operating Expenses	-	-	-	-	-	-	618,936	294,976	93,106	15,789
S&GA Expenses	-0.5%	2,831,000	2,845,000	3,098,000	2,493,000	2,574,000	1,797,000	1,203,000	981,000	-
R&D Expenses	-0.5%	6,574,000	6,608,000	3,824,000	5,670,000	6,115,000	2,858,000	2,864,000	2,743,000	-
EBITDA Margin	-Infinity%	-208	-	-	-	-	-	-	-	-
Income Taxes	410.0%	51,000	10,000	3,000	3,000	-	47,776	-	69,256	8,212
Earnings Before Taxes	-3.8%	-10,406,000	-10,021,000	-	-8,399,000	-	-244,403	114,720	349,864	18,670
EBT Margin	-20.2%	-228	-190	-190	-190	-190	-	-	-	-
Net Income	-4.2%	-10,457,000	-10,031,000	-7,336,000	-8,402,000	-9,144,000	-4,260,000	-3,778,000	-3,225,000	10,458
Net Income Margin	-3.8%	-229	-220	-213	-206	-190	-	-	-	-
Free Cashflow	-31.4%	-9,193,000	-6,995,000	-7,237,000	-7,830,000	-7,469,000	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-24.3%	25.00	33.00	41.00	41.00	46.00	52.00	58.00	69.00	78.00	82.00	62.00	67.00	70.00	75.00	78.00	84.00	92.00	71.00	72.00	71.00	45.00
Current Assets	-30.3%	18.00	25.00	33.00	33.00	37.00	43.00	48.00	58.00	67.00	70.00	50.00	57.00	61.00	65.00	71.00	77.00	85.00	0.00	1.00	1.00	40.00
Cash Equivalents	-29.3%	16.00	22.00	30.00	29.00	31.00	38.00	39.00	46.00	63.00	68.00	46.00	39.00	37.00	54.00	60.00	65.00	72.00	12.00	16.00	7.00	9.00
Net PPE	-6.6%	4.00	4.00	4.00	5.00	5.00	5.00	5.00	5.00	6.00	6.00	5.00	4.00	2.00	2.00	2.00	2.00	2.00	-	-	-	1.00
Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00	1.00	1.00	1.00
Current Liabilities	-12.6%	11.00	13.00	12.00	10.00	8.00	7.00	6.00	10.00	11.00	9.00	8.00	8.00	7.00	5.00	3.00	4.00	6.00	1.00	0.00	0.00	2.00
Long Term Debt	-100.0%	-	6.00	5.00	5.00	4.00	12.00	13.00	14.00	14.00	14.00	5.00	5.00	5.00	4.00	1.00	1.00	1.00	-	-	-	-
LT Debt, Non Current	-20.7%	5.00	7.00	8.00	9.00	11.00	12.00	13.00	14.00	14.00	14.00	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-62.2%	3.00	8.00	16.00	16.00	21.00	27.00	33.00	40.00	48.00	53.00	49.00	54.00	57.00	66.00	74.00	79.00	84.00	34.00	38.00	42.00	43.00
Retained Earnings	-3.5%	-162	-157	-149	-	-136	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00
Additional Paid-In Capital	0.3%	166	166	165	159	158	157	157	157	156	151	137	135	130	129	128	127	127	5.00	5.00	5.00	64.00
Shares Outstanding	0.0%	46.00	46.00	46.00	33.00	30.00	30.00	30.00	30.00	30.00	28.00	24.00	24.00	23.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	19.00	-	-	-	120	-	-	-	100	-	-	-	69.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-5.4%	-6,242	-5,922	-4,077	-5,045	-7,168	-5,476	-9,085	-7,363	-9,090	-5,684	-6,447	-6,352	-7,122	-5,918	-4,557	-6,850	-7,074	-269	-1,495	-3,040	-75.29
Share Based Compensation	114.4%	418	195	271	175	367	363	184	615	585	1,027	1,095	530	762	1,114	677	337	58.00	249	327	304	-
Cashflow From Investing	81.3%	-6.00	-32.00	-1.00	1,990	1,468	4,499	1,946	-10,020	-103	-1,311	12,419	5,168	-9,808	-193	-527	-329	8,109	170	11,864	-192	-
Cashflow From Financing	-1.3%	-1,324	-1,307	4,480	1,050	-	236	19.00	37.00	3,980	28,064	879	4,357	13.00	38.00	52.00	31.00	59,711	-500	-10.55	1,800	70,899

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PHGE Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Research and development (“R&D”) expenses, net	$ 16,698	$ 16,244
Amortization of intangible assets		1,519
General and administrative expenses	8,650	9,456
Operating loss	25,348	27,219
Other income	(357)	(134)
Interest expenses	2,404	2,069
Finance income, net	(1,249)	(902)
Loss before tax	26,146	28,252
Tax expenses	23	65
Net Loss	$ 26,169	$ 28,317
Basic loss per share of Common Stock (in Dollars per share)	$ 0.51	$ 0.95
Weighted average number of shares of Common Stock outstanding, basic (in Shares)	51,330,324	29,854,003

PHGE Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 14,907	$ 31,332
Restricted cash	957	962
Short-term deposits		2,000
Other current assets	1,768	2,587
Total current assets	17,632	36,881
Non-current assets
Operating lease right-of-use assets	3,495	3,860
Property and equipment, net	3,902	4,790
Total non-current assets	7,397	8,650
Total Assets	25,029	45,531
Current liabilities
Trade account payables	1,381	820
Current portion of lease liabilities	666	687
Other account payables	3,344	2,150
Current portion of long-term debt	5,785	4,282
Total current liabilities	11,176	7,939
Non-current liabilities
Contract liability	1,976	1,976
Long-term debt, net of current portion	5,402	10,591
Operating lease liabilities, net of current portion	3,239	3,798
Other liabilities	155	188
Total non-current liabilities	10,772	16,553
Commitments and Contingencies
Stockholders’ equity
Preferred Stock, $0.0001 par value; Authorized - 1,000,000 shares as of December 31, 2023 and December 31, 2022. No shares issued and outstanding as of December 31, 2023 and December 31, 2022.
Common stock, $0.0001 par value (“Common Stock”); Authorized - 120,000,000 shares as of December 31, 2023 and December 31, 2022. Issued – 45,979,930 and 29,982,282 as of December 31, 2023 and 2022, respectively. Outstanding – 45,979,930 and 29,976,582 as of December 31, 2023 and 2022, respectively.	3	2
Additional paid in capital	166,048	157,838
Accumulated deficit	(162,970)	(136,801)
Total stockholders’ equity	3,081	21,039
Total liabilities and stockholders’ equity	$ 25,029	$ 45,531

About BiomX Inc

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

CEO	Mr. Jonathan Eitan Solomon MBA
WEBSITE	biomx.com
INDUSTRY	Biotechnology
EMPLOYEES	54

BiomX Inc Frequently Asked Questions

What is the ticker symbol for BiomX Inc? What does PHGE stand for in stocks?

PHGE is the stock ticker symbol of BiomX Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BiomX Inc (PHGE)?

As of Fri May 03 2024, market cap of BiomX Inc is 20.98 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PHGE stock?

You can check PHGE's fair value in chart for subscribers.

What is the fair value of PHGE stock?

You can check PHGE's fair value in chart for subscribers. The fair value of BiomX Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of BiomX Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PHGE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is BiomX Inc a good stock to buy?

The fair value guage provides a quick view whether PHGE is over valued or under valued. Whether BiomX Inc is cheap or expensive depends on the assumptions which impact BiomX Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PHGE.

What is BiomX Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, PHGE's PE ratio (Price to Earnings) is -0.8 and Price to Sales (PS) ratio is 132.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PHGE PE ratio will change depending on the future growth rate expectations of investors.